AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. is a medical device company focused on developing and commercializing technologies for the treatment of atrial fibrillation (AF) and related cardiac conditions. Its products are used primarily in cardiac surgery and electrophysiology procedures to create surgical lesions that interrupt abnormal electrical signals in the heart.

The company’s portfolio includes the AtriCure Isolator Synergy ablation system, cryoablation products sold under the cryoICE brand, and the AtriClip system for the exclusion of the left atrial appendage, a potential source of blood clots in patients with AF. AtriCure also offers the EPi-Sense system, which is used in hybrid and minimally invasive procedures for AF treatment, as well as technologies designed to support the management of post-operative pain.

Founded in 2000, AtriCure is headquartered in Mason, Ohio. The company serves hospitals, cardiac surgeons, electrophysiologists and other healthcare providers in the United States and international markets through direct operations and distribution relationships. Its products are intended to support open, minimally invasive and hybrid approaches to cardiac care.

Key Stats

• Today's Range: $53.43 to $56.58
• 50-Day Range: $37.76 to $60.77
• 52-Week Range: $25.36 to $61.70
• Volume: 863,660 shs
• Average Volume: 1.67 million shs
• Market Capitalization: $2.73 billion
• P/E Ratio: 255.63
• Dividend Yield: N/A
• Price Target: $53.30
• Consensus Rating: Moderate Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 52% of companies evaluated by MarketBeat, and ranked 462nd out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AtriCure has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 55.17%

Earnings Growth

Earnings for AtriCure are expected to grow by 55.17% in the coming year, from $0.29 to $0.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is 255.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.01.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is 255.63, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.94.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 5.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.76% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently increased by 3.34%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.22

News Sentiment

AtriCure has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for AtriCure this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

3 people have added AtriCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,317,897.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/23/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,350
• Year Founded: 2000

Price Target and Rating

• Average Price Target for AtriCure: $53.30
• High Price Target: $65.00
• Low Price Target: $36.00
• Potential Upside/Downside: -0.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 255.63
• Forward P/E Ratio: 185.10
• P/E Growth: N/A
• Net Income: -$11.45 million
• Net Margins: 1.85%
• Pretax Margin: 2.12%
• Return on Equity: 2.34%
• Return on Assets: 1.77%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 4.22
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $569.62 million
• Price / Sales: 4.79
• Cash Flow: $0.30 per share
• Price / Cash Flow: 180.10
• Book Value: $9.89 per share
• Price / Book: 5.43

Miscellaneous

• Outstanding Shares: 50,866,000
• Free Float: 48,831,000
• Market Cap: $2.73 billion
• Optionable: Optionable
• Beta: 1.24